Results 151 to 160 of about 22,482 (226)

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. [PDF]

Ophthalmol Ther
Loewenstein A, Schmidt-Ott U, Do DV, Lanzetta P, Leal S, Berliner AJ, Chu KW, Barakat MR, Ghorayeb G, Stewart MW, Spitzer MS, Zhang X, McCullough A, Tueckmantel C, Avila D, Morgan-Warren P, Brunck L, Dupljak A, Hymowitz M, Portnoy A, Gale R.   +20 more
europepmc   +1 more source

A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel N.   +8 more
europepmc   +1 more source

Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry. [PDF]

Ophthalmol Ther
Timoceanu L, Steinmann S, Gillies MC, Barthelmes D.   +3 more
europepmc   +1 more source

Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration. [PDF]

Ophthalmol Sci
Razavi S, Menna M, Fragiotta S, Van Herreweghe S, Lazzerini A, Battista M, Beretta F, Sacconi R, Querques G.   +8 more
europepmc   +1 more source

Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU^®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis. [PDF]

Ophthalmol Ther
Servin AE, McFadden I, Esmaeilkhanian H, Holcomb D, Lin J, Awh CC.   +5 more
europepmc   +1 more source

Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials. [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel NA.   +8 more
europepmc   +1 more source

Short-term intraocular pressure changes following intravitreal aflibercept 8 mg versus 2 mg in diabetic macular edema: a prospective observational study. [PDF]

Sci Rep
Hoshiyama K, Hirano T, Sekiya E, Kajiwara S, Mukawa S, Chiku Y, Nakamura M, Yoshida N, Murata T.   +8 more
europepmc   +1 more source

Aflibercept and Faricimab Equipotently Restore Endothelial Barrier Function. [PDF]

Invest Ophthalmol Vis Sci
Strunz T, Rao M, Prinz F, Toedling J, Lesche R, Mielke J, Tetzner R, Lange C, Brunck L.   +8 more
europepmc   +1 more source

Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. [PDF]

BMJ Open Ophthalmol
Chauhan R, Gupta V, Natesh S, Vohra R, Agarwal V, Ganapathi PC, Bose D, Loganathan S.   +7 more
europepmc   +1 more source

Non-infectious occlusive retinal vasculitis following switching from aflibercept 2 mg to aflibercept 8 mg in neovascular age-related macular degeneration: a case report. [PDF]

BMC Ophthalmol
Simaku E, Eddien AN, Popa M, Shafei AE.
europepmc   +1 more source